Literature DB >> 15853748

Inflammatory mediators as potential therapeutic targets in the spine.

Sally Roberts1, Robin C Butler.   

Abstract

Inflammation plays a variable part in the pathogenesis of several spinal disorders. Ankylosing spondylitis is a chronic inflammatory arthropathy of the spine and rheumatoid arthritis, whilst affecting predominantly limb joints, also affects the cervical spine in a significant proportion of people. Inflammation is also involved in disorders such as disc herniation and sciatica, which have previously been thought of as being primarily mechanical or degenerative. Anti-inflammatory agents which have been shown to be effective elsewhere in the body are discussed in this review as possible therapeutic agents in the spine. As the inflammatory cascade and immunopathology of these conditions continue to be elucidated, it has become apparent that individual molecules may be potential targets for inactivation or down-regulation. Candidates include pro-inflammatory cytokines, such as TNF-alpha, cytokines, e.g. IL-1 and IL-15, or enzymes enhancing the inflammation pathway such as the cyclooxygenases. Hence treatments based on inactivation of these molecules by various mechanisms, including antibodies, receptor antagonists, enzyme inhibitors or gene therapy, are being introduced. However, the mode of action of a particular molecule can be complex and sometimes apparently contradictory. For example, TNF-alpha is known to play an important role in promoting inflammation by upregulating expression of cell adhesion molecules on endothelial cells and stimulating the production of reactive oxygen intermediates, nitric oxide and prostaglandins. However, it can also have an immunosuppressive and anti-inflammatory role after prolonged release. Therefore, although inhibitors of many of these molecules are now in clinical application and trials (many with promising results in rheumatoid arthritis), it is important to remain vigilant and monitor long-term outcomes particularly when these treatments are used in clinical syndromes with relatively poorly defined immunopathology such as spinal disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15853748     DOI: 10.2174/1568010053586372

Source DB:  PubMed          Journal:  Curr Drug Targets Inflamm Allergy        ISSN: 1568-010X


  8 in total

Review 1.  Disc cell therapies: critical issues.

Authors:  Marta Tibiletti; Nevenka Kregar Velikonja; Jill P G Urban; Jeremy C T Fairbank
Journal:  Eur Spine J       Date:  2014-02-08       Impact factor: 3.134

Review 2.  Inflammation in intervertebral disc degeneration and regeneration.

Authors:  Maria Molinos; Catarina R Almeida; Joana Caldeira; Carla Cunha; Raquel M Gonçalves; Mário A Barbosa
Journal:  J R Soc Interface       Date:  2015-03-06       Impact factor: 4.118

3.  Applicability of a newly developed bioassay for determining bioactivity of anti-inflammatory compounds in release studies--celecoxib and triamcinolone acetonide released from novel PLGA-based microspheres.

Authors:  Hsiao-yin Yang; Maarten van Dijk; Ruud Licht; Michiel Beekhuizen; Mattie van Rijen; Martina Källrot Janstål; F Cumhur Öner; Wouter J A Dhert; Detlef Schumann; Laura B Creemers
Journal:  Pharm Res       Date:  2014-08-28       Impact factor: 4.200

4.  The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis.

Authors:  Marina Stolina; Brad Bolon; Scot Middleton; Denise Dwyer; Heather Brown; Diane Duryea; Li Zhu; Alison Rohner; James Pretorius; Paul Kostenuik; Ulrich Feige; Debra Zack
Journal:  J Clin Immunol       Date:  2008-08-26       Impact factor: 8.317

5.  The presence and absence of lymphatic vessels in the adult human intervertebral disc: relation to disc pathology.

Authors:  Karolina Kliskey; Kelly Williams; J Yu; David Jackson; Jill Urban; Nick Athanasou
Journal:  Skeletal Radiol       Date:  2009-12       Impact factor: 2.199

Review 6.  Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy.

Authors:  Brad Bolon; Marina Stolina; Caroline King; Scot Middleton; Jill Gasser; Debra Zack; Ulrich Feige
Journal:  J Biomed Biotechnol       Date:  2010-12-28

7.  RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.

Authors:  Marina Stolina; Georg Schett; Denise Dwyer; Steven Vonderfecht; Scot Middleton; Diane Duryea; Efrain Pacheco; Gwyneth Van; Brad Bolon; Ulrich Feige; Debra Zack; Paul Kostenuik
Journal:  Arthritis Res Ther       Date:  2009-12-11       Impact factor: 5.156

8.  EGR1 controls divergent cellular responses of distinctive nucleus pulposus cell types.

Authors:  Guus G H van den Akker; Don A M Surtel; Andy Cremers; Martijn F G A Hoes; Marjolein M Caron; Stephen M Richardson; Ricardo Rodrigues-Pinto; Lodewijk W van Rhijn; Judith A Hoyland; Tim J M Welting; Jan Willem Voncken
Journal:  BMC Musculoskelet Disord       Date:  2016-03-14       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.